pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·3h ago·1 min read
save

Oura cancels planned IPO citing market uncertainty despite strong demand

Sep 29, 2026·read at Endpoints ↗DealNeutral

Oura, known for its smart ring, announced it is withdrawing its initial public offering.

The company said the decision was driven by ongoing uncertainty in the IPO market, even though it continues to see strong demand from investors.

The move highlights the broader challenges facing tech firms seeking public listings in a volatile financing environment.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Oura just pulled its IPO”

read at Endpoints ↗
78 words · retrieved 2h ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoPhRMA picks Eric Cantor as next chiefEndpoints
  • 2h agoSK pharmteco unveils $200M+ investment to expand CDMO capabilitiesEndpoints
  • 3h agoAscletis challenges psoriasis field with pill; Invivyd plans Covid filingEndpoints
  • 3h agoUniQure sinks as Huntington's gene therapy appears to show waning benefit over timeEndpoints
  • 4h agoARCH and Population Health return to China for new startup Somnivera, targeting sleepEndpoints